This is the authors' abstract. We don't add key points for this paper.
Background: Azithromycin (AZT) has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. Objective: To assess the association between exposure to AZT in patients with COVID-19, both admitted to the hospital and treated as outpatients, with respect to the duration of their clinical course and mortality. Methodology: An observational and retrospective case control-study paired by sex, age group (> and = <65 years), presence or absence of chronic diseases, and severity (presence or absence of pneumonia) was conducted March 15, 2020 to March 15, 2021, in a general medicine office in Toledo, Spain. Results: 19 cases and 19 controls were included. 26% of the cases and 42% of the controls had a positive clinical result (improvement or clinical cure before 13 days of the onset of the disease) (Fisher exact test = 0.1051; Paired OR = 0.4545 (Confidence intervals at 95%: 0.1579, 1.308). In the 19 cases there were no deaths vs. 2 deaths in the control group (Fisher exact test = 0.0001; paired OR = 0.1053 (Confidence intervals at 95 % = 0.02452, 0.4519). Conclusions: In the context of general medicine in Toledo (Spain), AZT did not shorten the duration of clinical symptoms, but it was shown to be a protective factor against mortality. Due to the limitations of the study design, the results should be considered with caution and the use of AZT in COVID-19 should be probably restricted, to date, to patients in whom there is an antimicrobial indication.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
José Luis Turabián (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: